EATG » Hepatitis

Hepatitis

Arrowhead receives regulatory clearance to begin Phase 1/2 study of ARO-HBV for treatment of hepatitis B

PASADENA, Calif., Feb 15, 2018 -- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and…

Does HIV coinfection influence HCV treatment duration?

Data published in HIV Medicine supports recent European Association for the Study of the Liver treatment guidelines suggesting there is no longer a need to differentiate between hepatitis C (HCV)…

Organ-on-chip technology enters next stage as experts test hepatitis B virus

Scientists at Imperial College London have become the first in the world to test how pathogens interact with artificial human organs. Artificial human organs, or organ-on-chip technologies, simulate a whole…

How can baby boomers become more HCV aware?

According to the Centers for Disease Control and Prevention (CDC), baby boomers are 5 times more likely to have hepatitis C (HCV) than other adults. Through IV drug abuse and…

Understanding spontaneous hepatitis C virus clearance

Among patients in the acute phase of hepatitis C virus (HCV) infection, a portion will spontaneously clear the infection without treatment, and HCV RNA will completely disappear from the serum.…

Study reveals the liver’s ‘weak spot’ for hepatitis B virus replication

In a surprising discovery, researchers from the Singapore Immunology Network (SIgN), A*STAR, have found that the liver is the main site of hepatitis B (HBV) replication—not only because it contains…

Hepatocellular carcinoma recurrence in HBV reduced with high-potency antivirals

Antiviral treatments with a high genetic barrier to resistance, such as entecavir and tenofovir disoproxil fumarate, reduced the risk for hepatocellular carcinoma (HCC) recurrence in patients with hepatitis B virus…

HCV in older adults: effects of prolonged infection, aging-related mechanisms, and treatment

More than 4 million people have been exposed to hepatitis C virus (HCV) in the United States.1 Although the rate of new HCV infections has decreased in recent decades because…

Seven recent reports on HBV treatment approvals, efficacy

Direct-acting antivirals have provided a highly viable cure for hepatitis C, but hepatitis B remains a complicated infectious disease and requires lengthy treatment and management in chronic cases. While HBV…

Compounds isolated from rattlesnake venom show activity against hepatitis C virus

Studies conducted by Brazilian researchers and published in PLOS ONE and Scientific Reports also found compounds derived from Brazilian plants to be promising against hepatitis C. A group of Brazilian…